gemcitable alone:Intravenously at a dose of 1000 mg/m2 on days 1, 8, and 15 of each 4-week cycle

2 trials

Sponsors

Shanghai Sixth People's Hospital

Conditions

Hilar cholangiocarcinoma

Phase 4

The outcome of gemcitabine, sorafenib and S1 combination in the treatment of inoperable hilar cholangiocarcinoma

Active, not recruitingChiCTR-TRC-14004737

Shanghai Sixth People's HospitalHilar cholangiocarcinoma

Start: 2014-06-08Updated: 2017-04-18

Unknown Phase

The outcome of gemcitabine and S1 combination in the treatment of inoperable hilar cholangiocarcinoma

Active, not recruitingChiCTR-TRC-14004733

Shanghai Sixth People's HospitalHilar cholangiocarcinoma

Start: 2009-02-05Updated: 2017-04-18

Related Papers

Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial

Oncotarget2016-04-0525 citations